Key Points
-
Medtronic recently completed a key spinoff of its diabetes segment.
-
The company is on the cusp of becoming a Dividend King.
-
Medtronic’s stock is underpriced compared to medical device peers.
-
Medtronic (NYSE: MDT) is entering new waters after spinning off its diabetes segment, now called MiniMed (NASDAQ: MMED). The hope for the medical devices company is that the move will unlock greater margins.
It’s already helped the stock in one way. As part of the deal, Medtronic received approximately 55 million of its own shares in the final results of its oversubscribed split-off and exchange offer for MiniMed. That means Medtronic’s future net income will be distributed across a smaller number of shares, making it easier for the company to increase earnings per share (EPS).
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Investors have been a bit dubious about the stock, despite strong financials. It’s down just under 1% so far this year, but over the last three months, it has climbed more than 11%. Here are three reasons why Medtronic might be a buy.
It’s about to become a Dividend King
The list of Dividend Kings is a small one. Out of roughly 7,000 stocks on major U.S. exchanges, only 59 have made it to the list by increasing their dividends for 50 or more consecutive years.
Companies on that list have survived multiple recessions and market crashes, all while maintaining cash-flow stability and market competitiveness. It’s an elite list that investors pay attention to, and Medtronic has increased its dividend for 49 consecutive years, including a 1.4% increase in 2026. If it raises its dividend in 2027, as expected, the milestone will likely boost stock sales as institutional inflows and fund rebalancing increase.
The company’s trailing cash dividend payout ratio is just under 60%, leaving plenty of room for additional dividend increases.
Strong financials, anticipated growth
In the first quarter of fiscal 2027 — the quarter ended July 31 — Medtronic reported revenue of $9.8 billion, up nearly 14%, year over year. The bump was led by the company’s cardiovascular segment, in which revenue rose by 19% over the same period last year. The company’s two remaining segments, neuroscience and medical surgical, saw revenue rise 14% and 9%, respectively.
EPS rose 15%, year over year, to $1.45. Medtronic had previously forecast yearly organic revenue to increase between 7.25% and 7.75%, and for yearly EPS to rise between 7.4% and 8.5%. However, the guidance was released before the company’s MiniMed spinoff, so those numbers will change.
In fiscal 2026, the healthcare company reported its second great year of growth after a long period of so-so returns. It reported 2026 revenue of $36.4 billion, an 8.4% increase.
The key is a reinvigorated pipeline. The company had more than 50 new FDA approvals and clearances in fiscal 2026, including approvals for its Stealth AXiS computer-assisted surgical system for cranial, ear, nose, and throat, and spine procedures and its Hugo robotic surgery system for urological procedures.
The stock is underpriced
Despite the company’s operational rebound and revenue acceleration, Medtronic stock trades at a discount compared to medtech peers.
It is trading at roughly 16 times forward earnings estimates and 24 times trailing earnings, well below competitors such as Johnson & Johnson (NYSE: JNJ), Edwards Lifesciences (NYSE: EW), Abbott Labs (NYSE: ABT), and Stryker (NYSE: SYK). Medtronic also boasts an earnings yield of 4.2%, again outperforming its closest medtech competitors.
MDT PE Ratio (Forward) data by YCharts
Should you buy stock in Medtronic right now?
Before you buy stock in Medtronic, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $334,793!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,257,420!*
Now, it’s worth noting Stock Advisor’s total average return is 874% — a market-crushing outperformance compared to 209% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 1, 2026.
James Halley has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Abbott Laboratories, Edwards Lifesciences, and Medtronic. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
